Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET

Company Participants

Philip Trip Taylor - Investor Relations
Paul Badawi - Co-Founder & Chief Executive Officer
Alison Bauerlein - Chief Financial Officer
Matt Link - Chief Commercial Officer

Conference Call Participants

Macauley Kilbane - William Blair
Phil Dantoin - Piper Sandler
Nelson Cox - Lake Street Capital Markets
Tom Stephan - Stifel

Operator

Thank you for standing by. My name is Janine, I will be your conference operator for today. At this time, I would like to welcome everyone to Sight Sciences' Third Quarter 2024 Earnings Results Call. All lines have been placed on mute to prevent any background noise. Today's presentation, there will an opportunity to ask questions. [Operator Instructions]

I would like to turn the conference over to Trip from Investor Relations. Please go ahead.

Philip Trip Taylor

Thank you for participating in today's call. Presenting today are Sight Sciences' Co-Founder and Chief Executive Officer, Paul Badawi; and Chief Financial Officer, Ali Bauerlein. Also in attendance is Sight Sciences' Chief Commercial Officer, Matt Link.

Earlier today, Sight Sciences released financial results for the three months ended September 30, 2024, and reaffirmed revenue guidance and updated adjusted operating expense guidance for full year 2024. A copy of the press release is available on the company's website at investors.sightsciences.com.

I'd like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include statements related to the company's anticipated financial performance, operating results, liquidity position and ability to achieve cash flow breakeven and 2024 revenue and adjusted operating expenses guidance, ability to achieve current and long-term strategic objectives, market opportunity and ability to enter new markets and capture market share, pricing strategy, product reimbursement coverage and strategy, expectations regarding regaining commercial momentum, account utilization and engagement, clinical trial strategy and results and the disposition of ongoing patent litigation.

Forward-looking statements are based on estimates and assumptions as of today are neither promises nor guarantees and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements. A description of some of the risks and uncertainties that could cause actual results to differ materially from those indicated by the forward-looking statements on this call can be found in the company's public filings with the Securities and Exchange Commission, including in the Risk Factors section of its annual report on Form 10-K and quarterly reports on Form 10-Q. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.